APOE and hepatocellular carcinoma: We subsequently built a second cohort of 360 HCC patients to investigate how apoE subtypes, expression and infiltration of MDSCs in the HCC tissues affect patients’ survival, to examine its potential as a biomarker for HCC patients’ prognosis and as a therapeutic target.